kandeel eman (11 resultados)

Condición: New. In.

Paperback. Condición: New.

Taschenbuch. Condición: Neu. Flow Cytomteric Detection of Minimal Residual Disease | MRD in Acute leukemia | Eman Kandeel (u. a.) | Taschenbuch | 144 S. | Englisch | 2013 | LAP LAMBERT Academic Publishing | EAN 9783659405761 | Verantwortliche Person für die EU: OmniScriptum GmbH & Co. KG, Bahnhofstr. 28, 66111 Saarbrücken, info[at]akademikerverlag[dot]de | Anbieter: preigu.

Paperback. Condición: Like New. Like New. book.

PAP. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

PAP. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -A crucial problem for oncologist in treatment of acute leukemia is the characterization of patients who require more intensification of therapy to avert relapse. Although clinical (e.g., age, gender) and biologic (e.g., white blood cell count, immunophenotype, structural chromosomal abnormalities, and gene rearrangements) factors can be used for treatment stratification, none of these prognostic parameters is optimal. A proportion of patients with 'low risk' experiences relapse, while others may receive more aggressive treatment than is necessary. Studies of minimal residual disease (MRD) focus at improving the estimation of leukemic burden during treatment. This information provides an indicator of the aggressiveness and drug sensitivity of the disease and guide in the selection of appropriate therapeutic strategies. 144 pp. Englisch.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Kandeel EmanEman Z Kandeel MD Bone marrow transplantation Lab National cancer institute of Egypt Cairo universityA crucial problem for oncologist in treatment of acute leukemia is the characterization of patients who require more.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Ali Eman Abdalla IbrahemEman Abdalla Ibrahem AliB.Sc. Environmental Agricultural Sciences, 2011Suez Canal University. Master of ScienceEl-Arish University, 2016. I m greatly indebted to Prof. Dr. Mohamed Hassan Kandeel, For supervis.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -A crucial problem for oncologist in treatment of acute leukemia is the characterization of patients who require more intensification of therapy to avert relapse. Although clinical (e.g., age, gender) and biologic (e.g., white blood cell count, immunophenotype, structural chromosomal abnormalities, and gene rearrangements) factors can be used for treatment stratification, none of these prognostic parameters is optimal. A proportion of patients with ¿low risk¿ experiences relapse, while others may receive more aggressive treatment than is necessary. Studies of minimal residual disease (MRD) focus at improving the estimation of leukemic burden during treatment. This information provides an indicator of the aggressiveness and drug sensitivity of the disease and guide in the selection of appropriate therapeutic strategies.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 144 pp. Englisch.

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - A crucial problem for oncologist in treatment of acute leukemia is the characterization of patients who require more intensification of therapy to avert relapse. Although clinical (e.g., age, gender) and biologic (e.g., white blood cell count, immunophenotype, structural chromosomal abnormalities, and gene rearrangements) factors can be used for treatment stratification, none of these prognostic parameters is optimal. A proportion of patients with 'low risk' experiences relapse, while others may receive more aggressive treatment than is necessary. Studies of minimal residual disease (MRD) focus at improving the estimation of leukemic burden during treatment. This information provides an indicator of the aggressiveness and drug sensitivity of the disease and guide in the selection of appropriate therapeutic strategies.